A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.

Moshe C OrnsteinLaura S WoodBrian P HobbsKimberly D AllmanAllison MartinMichael BevanTimothy D GilliganJorge A GarciaBrian I Rini

Published in: Journal for immunotherapy of cancer (2019)

NCT03126331 (Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients; Date of registration 4/27/2017; https://clinicaltrials.gov/ct2/show/NCT03126331 ).

Keyphrases

metastatic renal cell carcinoma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
computed tomography
high intensity
peritoneal dialysis
randomized controlled trial
clinical trial
bone marrow
magnetic resonance
mesenchymal stem cells
contrast enhanced
dual energy